Triple-negative breast cancer (TNBC) is an aggressive and metabolically active form of breast cancer with high rates of symptomatic metastases, and comprises approximately 10%-20% of all female breast cancer cases.

The Phase 2/3 TRYbeCA-2 trial is evaluating eryaspase in combination with gemcitabine and carboplatin chemotherapy, compared to chemotherapy alone as treatment of patients with metastatic TNBC.

Following the disappointing results of eryaspase in combination with a gemcitabine-based chemotherapy in the TRYbeCA-1 trial in second-line pancreatic cancer, the Company has, in consultation with the trial’s Steering Committee, decided to stop further enrollment in the TRYbeCA-2 trial.

The results of the patients enrolled in the TRYbeCA-2 trial to date are expected to be reported in the second half of 2022.